 Home > Medical News > Latest Medical News > Shutaishen STSA-1002 injection was approved for clinical use in the United States

Shutaishen STSA-1002 injection was approved for clinical use in the United States

 Last Update: 2021-08-03
 Source: Internet
 Author: User

Tags

5 1 phone

antibody drug conjugate

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On July 19, Shutaishen issued an announcement stating that it had received a notification email from the US FDA, and started clinical trials with STSA-1002 injection for the treatment of severe COVID-19 indications

STSA-1002 injection is a recombinant anti-human C5a IgG1 fully human monoclonal antibody targeting C5a.

In recent years, with the continuous deepening of basic research, the role of the complement system in a variety of major diseases has received more and more attention and affirmation

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.